Answers are grounded in this paper and cite their sources.
Large part of the current research in the field of psoriasis is directed towards identifying and characterising new biomarkers, for both diagnostic and prognostic purposes at clinical settings.This will help in developing prompt and effective therapeutic approaches, particularly to manage the cardiovascular risk factors often associated with psoriasis, to reduce cardiovascular morbidity.This review highlights the biomarkers that have been identified to date, that are accessible and very useful to primary care physicians (PCPs), because, in most cases, these are the first indicators of psoriasis in the patients.We have focussed on the inflammatory and oxidative stress pathways to identify inflammatory biomarkers that link cardiovascular disease (CVD) risk with psoriasis, in both sexes.In addition, we have separately collated the information specific to women, unlike previous reviews.Our review also emphasises the importance of staying abreast of the advances in the field, to understand the comorbidities of psoriasis.With new therapeutic approaches that offer novel treatment options, chances of detecting the comorbidities, even in their subclinical phase, improve.This can lead to accelerated clearance of skin lesions, and improved quality of life for the patients.
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.